RECURRENT HODGKIN LYMPHOMA
Clinical trials for RECURRENT HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo trial aims to reawaken immune system against stubborn lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a two-drug combination for people with B-cell lymphomas that have come back or stopped responding to other treatments. The treatment pairs an immunotherapy drug (nivolumab) with a pill (ASTX727) that may help the immun…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Custom immune cells fight blood cancers after transplant
Disease control Recruiting nowThis study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Mega-Dose vitamin c joins fight against stubborn blood cancers
Disease control Recruiting nowThis study is testing if adding high-dose vitamin C (given through an IV) to standard chemotherapy can help patients whose lymphoma has returned or hasn't responded to treatment. It also tests vitamin C alone for certain pre-leukemia conditions. The goal is to see if vitamin C ma…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Radioactive 'Warhead' targets tough hodgkin lymphoma in new transplant strategy
Disease control Recruiting nowThis study is testing a new two-part treatment for Hodgkin lymphoma that has not responded to or has returned after initial therapy. First, a radioactive antibody is given to seek out and kill cancer cells. Then, high-dose chemotherapy and a patient's own stem cells are used to t…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC